NCT05470348View on ClinicalTrials.gov

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 11, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Breast CancerSolid Tumor

Interventions

DRUG

BL-B01D1

Administration by intravenous infusion

Trial Locations (2)

200032

RECRUITING

Fudan University ShangHai Cancer Center, Shanghai

Unknown

RECRUITING

Guangdong Provincial People's Hospital, Guangzhou

All Listed Sponsors

collaborator

SystImmune Inc.

INDUSTRY

collaborator

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.

INDUSTRY

lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY

NCT05470348 - A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors | Biotech Hunter | Biotech Hunter